These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 21954897)

  • 1. Intravenous epinephrine infusion test in diagnosis of catecholaminergic polymorphic ventricular tachycardia.
    Marjamaa A; Hiippala A; Arrhenius B; Lahtinen AM; Kontula K; Toivonen L; Happonen JM; Swan H
    J Cardiovasc Electrophysiol; 2012 Feb; 23(2):194-9. PubMed ID: 21954897
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mutant ryanodine receptors in catecholaminergic polymorphic ventricular tachycardia generate delayed afterdepolarizations due to increased propensity to Ca2+ waves.
    Paavola J; Viitasalo M; Laitinen-Forsblom PJ; Pasternack M; Swan H; Tikkanen I; Toivonen L; Kontula K; Laine M
    Eur Heart J; 2007 May; 28(9):1135-42. PubMed ID: 17347175
    [TBL] [Abstract][Full Text] [Related]  

  • 3. High prevalence of exercise-induced arrhythmias in catecholaminergic polymorphic ventricular tachycardia mutation-positive family members diagnosed by cascade genetic screening.
    Haugaa KH; Leren IS; Berge KE; Bathen J; Loennechen JP; Anfinsen OG; Früh A; Edvardsen T; Kongsgård E; Leren TP; Amlie JP
    Europace; 2010 Mar; 12(3):417-23. PubMed ID: 20106799
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Familial evaluation in catecholaminergic polymorphic ventricular tachycardia: disease penetrance and expression in cardiac ryanodine receptor mutation-carrying relatives.
    van der Werf C; Nederend I; Hofman N; van Geloven N; Ebink C; Frohn-Mulder IM; Alings AM; Bosker HA; Bracke FA; van den Heuvel F; Waalewijn RA; Bikker H; van Tintelen JP; Bhuiyan ZA; van den Berg MP; Wilde AA
    Circ Arrhythm Electrophysiol; 2012 Aug; 5(4):748-56. PubMed ID: 22787013
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical characteristics and mutational analysis of the RyR2 gene in seven Czech families with catecholaminergic polymorphic ventricular tachycardia.
    Andrsova I; Valaskova I; Kubus P; Vit P; Gaillyova R; Kadlecova J; Manouskova L; Novotny T
    Pacing Clin Electrophysiol; 2012 Jul; 35(7):798-803. PubMed ID: 22519458
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Unusual clinical presentation in a family with catecholaminergic polymorphic ventricular tachycardia due to a G14876A ryanodine receptor gene mutation.
    Allouis M; Probst V; Jaafar P; Schott JJ; Le Marec H
    Am J Cardiol; 2005 Mar; 95(5):700-2. PubMed ID: 15721128
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A novel mutation in FKBP12.6 binding region of the human cardiac ryanodine receptor gene (R2401H) in a Japanese patient with catecholaminergic polymorphic ventricular tachycardia.
    Aizawa Y; Ueda K; Komura S; Washizuka T; Chinushi M; Inagaki N; Matsumoto Y; Hayashi T; Takahashi M; Nakano N; Yasunami M; Kimura A; Hiraoka M; Aizawa Y
    Int J Cardiol; 2005 Mar; 99(2):343-5. PubMed ID: 15749201
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Epinephrine infusion in the evaluation of unexplained cardiac arrest and familial sudden death: from the cardiac arrest survivors with preserved Ejection Fraction Registry.
    Krahn AD; Healey JS; Chauhan VS; Birnie DH; Champagne J; Sanatani S; Ahmad K; Ballantyne E; Gerull B; Yee R; Skanes AC; Gula LJ; Leong-Sit P; Klein GJ; Gollob MH; Simpson CS; Talajic M; Gardner M
    Circ Arrhythm Electrophysiol; 2012 Oct; 5(5):933-40. PubMed ID: 22944906
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Calcium channel antagonism reduces exercise-induced ventricular arrhythmias in catecholaminergic polymorphic ventricular tachycardia patients with RyR2 mutations.
    Swan H; Laitinen P; Kontula K; Toivonen L
    J Cardiovasc Electrophysiol; 2005 Feb; 16(2):162-6. PubMed ID: 15720454
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The role of stress test for predicting genetic mutations and future cardiac events in asymptomatic relatives of catecholaminergic polymorphic ventricular tachycardia probands.
    Hayashi M; Denjoy I; Hayashi M; Extramiana F; Maltret A; Roux-Buisson N; Lupoglazoff JM; Klug D; Maury P; Messali A; Guicheney P; Leenhardt A
    Europace; 2012 Sep; 14(9):1344-51. PubMed ID: 22383456
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Deadly proposal: a case of catecholaminergic polymorphic ventricular tachycardia.
    Heiner JD; Bullard-Berent JH; Inbar S
    Pediatr Emerg Care; 2011 Nov; 27(11):1065-8. PubMed ID: 22068070
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Catecholaminergic polymorphic ventricular tachycardia.
    Liu N; Ruan Y; Priori SG
    Prog Cardiovasc Dis; 2008; 51(1):23-30. PubMed ID: 18634915
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical and molecular characterization of patients with catecholaminergic polymorphic ventricular tachycardia.
    Priori SG; Napolitano C; Memmi M; Colombi B; Drago F; Gasparini M; DeSimone L; Coltorti F; Bloise R; Keegan R; Cruz Filho FE; Vignati G; Benatar A; DeLogu A
    Circulation; 2002 Jul; 106(1):69-74. PubMed ID: 12093772
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Catecholaminergic polymorphic ventricular tachycardia: RYR2 mutations, bradycardia, and follow up of the patients.
    Postma AV; Denjoy I; Kamblock J; Alders M; Lupoglazoff JM; Vaksmann G; Dubosq-Bidot L; Sebillon P; Mannens MM; Guicheney P; Wilde AA
    J Med Genet; 2005 Nov; 42(11):863-70. PubMed ID: 16272262
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical and molecular characterization of a cardiac ryanodine receptor founder mutation causing catecholaminergic polymorphic ventricular tachycardia.
    Wangüemert F; Bosch Calero C; Pérez C; Campuzano O; Beltran-Alvarez P; Scornik FS; Iglesias A; Berne P; Allegue C; Ruiz Hernandez PM; Brugada J; Pérez GJ; Brugada R
    Heart Rhythm; 2015 Jul; 12(7):1636-43. PubMed ID: 25814417
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Catecholaminergic polymorphic ventricular tachycardia].
    Leren IS; Haugaa KH; Edvardsen T; Anfinsen OG; Kongsgård E; Berge KE; Leren TP; Amlie JP
    Tidsskr Nor Laegeforen; 2010 Jan; 130(2):139-42. PubMed ID: 20125202
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Catecholaminergic polymorphic ventricular tachycardia: recent mechanistic insights.
    Kontula K; Laitinen PJ; Lehtonen A; Toivonen L; Viitasalo M; Swan H
    Cardiovasc Res; 2005 Aug; 67(3):379-87. PubMed ID: 15913575
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Exon 3 deletion of RYR2 encoding cardiac ryanodine receptor is associated with left ventricular non-compaction.
    Ohno S; Omura M; Kawamura M; Kimura H; Itoh H; Makiyama T; Ushinohama H; Makita N; Horie M
    Europace; 2014 Nov; 16(11):1646-54. PubMed ID: 24394973
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Incidence and risk factors of arrhythmic events in catecholaminergic polymorphic ventricular tachycardia.
    Hayashi M; Denjoy I; Extramiana F; Maltret A; Buisson NR; Lupoglazoff JM; Klug D; Hayashi M; Takatsuki S; Villain E; Kamblock J; Messali A; Guicheney P; Lunardi J; Leenhardt A
    Circulation; 2009 May; 119(18):2426-34. PubMed ID: 19398665
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Different responses to exercise between Andersen-Tawil syndrome and catecholaminergic polymorphic ventricular tachycardia.
    Inoue YY; Aiba T; Kawata H; Sakaguchi T; Mitsuma W; Morita H; Noda T; Takaki H; Toyohara K; Kanaya Y; Itoi T; Mitsuhashi T; Sumitomo N; Cho Y; Yasuda S; Kamakura S; Kusano K; Miyamoto Y; Horie M; Shimizu W
    Europace; 2018 Oct; 20(10):1675-1682. PubMed ID: 29309601
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.